News
Significant adverse events — such as ARIA — with lecanemab, the drug that slows Alzheimer's, is rare and manageable, ...
The FDA-approved monoclonal antibody infusion known as donanemab, is showing promise to reduce cognitive decline among ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results